jonzobot, great find!

My hopes: (1) Apabetalone is effective against all variants: and (2) - which is related to (1) - folks who are ill with the variants of concern most likely come from patient population afflicted with T2D and CKD.  If that is the case, then I'm fairly confident that Apabetalone will provide statistically significant benefit.  Although, here in BC, Provincial Health Officer talks about demographics of hospitalized patients are now younger (there are a lot of variants of concern in BC)

Please feel free to tear my thinking apart...